Trametinib - Latest Advances

Takotsubo Syndrome Following Combination Therapy with Dabrafenib and Trametinib: Case Report.

Journal: Internal medicine (Tokyo, Japan)

Published: September 18, 2025

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.

Journal: bioRxiv : the preprint server for biology

Published: September 18, 2025

TuNa-AI: A Hybrid Kernel Machine To Design Tunable Nanoparticles for Drug Delivery.

Journal: ACS nano

Published: September 11, 2025

Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long-Term Exposure While Maintaining Efficacy.

Journal: Pediatric blood & cancer

Published: September 01, 2025

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Journal: Precision oncogenomics

Published: August 29, 2025

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 27, 2025

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

Journal: Pharmaceutical medicine

Published: August 26, 2025

Two Cases of BRAF V600K Melanoma With Recurrence During Adjuvant Dabrafenib Plus Trametinib Therapy.

Journal: The Journal of dermatology

Published: August 25, 2025

Immunotherapy in Melanoma.

Journal: Cancer treatment and research

Published: August 23, 2025

Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.

Journal: The Journal of clinical investigation

Published: August 19, 2025

Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 15, 2025

Treatment-Related Adverse Events in Individuals with BRAF-Mutant Cutaneous Melanoma Treated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis.

Journal: Cancers

Published: August 13, 2025

Filters

Takotsubo Syndrome Following Combination Therapy with Dabrafenib and Trametinib: Case Report.

Takotsubo Syndrome Following Combination Therapy with Dabrafenib and Trametinib: Case Report.

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.

TuNa-AI: A Hybrid Kernel Machine To Design Tunable Nanoparticles for Drug Delivery.

TuNa-AI: A Hybrid Kernel Machine To Design Tunable Nanoparticles for Drug Delivery.

Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long-Term Exposure While Maintaining Efficacy.

Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long-Term Exposure While Maintaining Efficacy.

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma.

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma.

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

Two Cases of BRAF V600K Melanoma With Recurrence During Adjuvant Dabrafenib Plus Trametinib Therapy.

Two Cases of BRAF V600K Melanoma With Recurrence During Adjuvant Dabrafenib Plus Trametinib Therapy.

Immunotherapy in Melanoma.

Immunotherapy in Melanoma.

Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.

Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.

Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.

Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.

Treatment-Related Adverse Events in Individuals with BRAF-Mutant Cutaneous Melanoma Treated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis.

Treatment-Related Adverse Events in Individuals with BRAF-Mutant Cutaneous Melanoma Treated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis.